Glioblastoma Multiforme Clinical Trials 2024

What are the top hospitals conducting glioblastoma multiforme research?

In the battle against glioblastoma multiforme, an aggressive form of brain cancer, several hospitals are leading the charge in groundbreaking clinical trials. One such institution is Dana-Farber Cancer Institute in Boston, where researchers have dedicated themselves to finding innovative solutions for this challenging condition. With 11 active glioblastoma multiforme trials and an impressive history of 65 completed studies dating back to their first recorded trial in 1998, Dana-Farber has established itself as a hub for cutting-edge research. Joining them on the frontlines is Memorial Sloan Kettering Cancer Center in New York. This renowned center has eight ongoing trials focused on glioblastoma multiforme and a rich legacy of 47 previous studies since initiating their first trial in 2002.

Additionally contributing significantly to this field is Washington University School of Medicine in Saint Louis, which conducts pioneering research through eight active clinical trials addressing glioblastoma multiforme while having accomplished an admirable tally of49 previously conducted studies since starting their earliest recorded trial in2006.Lenox Hill Brain tumor Center, also based out of New York City, may have fewer current clinical trials with only five actively running; however they too play vital role by building upon fifteen successful experiments carried out till date from when they started investigating this debilitating disease around same time i.e.,2006.Lastly but not least,the UniversityofCalifornia,SanFrancisco,in San Francisco demonstrates its commitment throughfiveongoingclinicaltestsand contributes meaningfullytothefieldwithtwenty-fivecompletedstudies.Theyinitiatedtheirfirstglioblastomamultiformetrialin2004

These prestigious medical institutions represent beacons of hope as they tirelessly work towards developing effective treatments or even potentially finding a cure for glioblastoma multiforme. Their dedication highlights the urgent need for advancements while offering solace to patients and families affected by this devastating condition across various geographical regions. By pooling their resources, knowledge, and expertise, these top hospitals are undeniably making strides towards a future where glioblastoma multiforme is no longer an insurmountable obstacle but rather a conquerable challenge.

Which are the best cities for glioblastoma multiforme clinical trials?

When it comes to glioblastoma multiforme clinical trials, several cities emerge as leading hubs for cutting-edge research and treatment options. New york, with its 32 active trials, focuses on studying treatments like INO-5401, Pemigatinib, RT plus TMZ and ENZ, among others. Boston follows closely behind with 29 ongoing trials investigating therapies such as Dose Escalation Cohorts - Monotherapy, Pembrolizumab, and Olaparib. Saint Louis showcases 21 active trials exploring Quality-of-Life Assessment measures along with treatments like Olaparib and Radiation Therapy. Furthermore, Los Angeles conducts 18 active trials that investigate various treatment combinations including RT plus TMZ and ENZ alongside Adavosertib or Surgery interventions. Lastly, Dallas presents 16 active trials examining Pemigatinib as well as Dose Escalation Cohorts - Monotherapy and Sacituzumab Govitecan-based approaches. These cities offer hope to individuals affected by glioblastoma multiforme by providing access to innovative clinical trials that pave the way for improved care outcomes.

Which are the top treatments for glioblastoma multiforme being explored in clinical trials?

[Glioblastoma multiforme](https://www.withpower.com/clinical-trials/glioblastoma-multiforme), a formidable brain cancer, has spurred extensive research into innovative treatment options. Temozolomide takes the lead with six ongoing clinical trials and an impressive 218 all-time trials dedicated to glioblastoma multiforme since its debut in 2002. Not far behind is nivolumab, showing promise in three active trials and contributing to a total of 27 all-time studies since it was first listed in 2014. Another key player is radiation therapy, currently being investigated in three ongoing trials after its introduction to glioblastoma multiforme research back in 2004. Intra-arterial cetuximab follows closely with two active and two historical trials since being listed as a potential treatment option for this aggressive cancer type in 2016. Rounding out the list is Ibrutinib—a newcomer making waves—currently involved in two active clinical trials after its initial listing for glioblastoma multiforme treatment just three years ago, in 2018. The pursuit of effective treatments continues unabated as researchers strive to improve outcomes for patients battling this relentless disease.

What are the most recent clinical trials for glioblastoma multiforme?

Exciting advancements are underway in the field of glioblastoma multiforme (GBM) research, with recent clinical trials showcasing promising potential for improved treatment options. These trials include a Phase 2 study that investigates autologous therapies and their efficacy in GBM patients. Additionally, a Phase 1 trial explores the impact of dose escalation in Group A participants. Another study focuses on newly diagnosed GBM patients, aiming to provide valuable insights into this challenging disease. Furthermore, a Phase 2 trial evaluates Stratum A's effectiveness by enrolling forty individuals with GBM. Lastly, researchers are examining the benefits of combining standard surgical treatment with intraoperative electrocorticography as an innovative approach to tackling GBM. With these cutting-edge studies at hand, there is renewed hope for those affected by glioblastoma multiforme.

What glioblastoma multiforme clinical trials were recently completed?

Recently completed clinical trials for glioblastoma multiforme have made significant strides in advancing treatment options. Among these trials, Washington University School of Medicine concluded their investigation into the efficacy of Tadalafil in May 2021, followed by Kiarash Shahlaie's Lidocaine trial in January 2021. In July 2020, Gan and Lee Pharmaceuticals' GLR2007 study reached completion. These recent achievements highlight the ongoing efforts to combat this aggressive form of brain cancer and provide hope for patients facing this challenging diagnosis.